Recombinant Human TNFSF12, N-His

Description of Recombinant Human TNFSF12, N-His

Introduction to Recombinant Human TNFSF12, N-His

Recombinant Human TNFSF12, N-His is a protein that has gained significant attention in the field of drug discovery and development. It is a modified version of the naturally occurring human TNFSF12 protein, also known as TWEAK (TNF-like weak inducer of apoptosis). This recombinant protein has been engineered to contain an additional histidine (His) tag at the N-terminus, making it easier to purify and study in laboratory settings.

Structure of Recombinant Human TNFSF12, N-His

The structure of Recombinant Human TNFSF12, N-His is similar to that of the native TNFSF12 protein. It is a trimeric protein, meaning it is composed of three identical subunits. Each subunit consists of a short N-terminal domain, a cysteine-rich domain, a stalk region, and a C-terminal TNF-like domain. The addition of the His tag does not affect the overall structure of the protein, as it is located at the N-terminus, away from the functional domains.

Activity of this protein

Recombinant Human TNFSF12, N-His is a potent activator of the NF-κB signaling pathway, which plays a crucial role in inflammation, cell survival, and immune response. This protein binds to its receptor, Fn14, on the surface of target cells, leading to the activation of NF-κB. This, in turn, triggers a cascade of downstream signaling events that regulate various cellular processes.

Additionally, Recombinant Human TNFSF12, N-His has been shown to induce apoptosis (programmed cell death) in certain cancer cells, making it a potential anti-cancer agent. It also has pro-inflammatory effects, promoting the production of cytokines and chemokines that recruit immune cells to the site of injury or infection.

Application of Recombinant Human TNFSF12, N-His

Due to its role in regulating the NF-κB pathway, Recombinant Human TNFSF12, N-His has been identified as a promising drug target for various diseases. It has been studied extensively in the context of autoimmune and inflammatory disorders, such as rheumatoid arthritis, multiple sclerosis, and psoriasis. By targeting TNFSF12, N-His, researchers hope to modulate the activity of NF-κB and reduce inflammation in these conditions.

Moreover, the ability of Recombinant Human TNFSF12, N-His to induce apoptosis in cancer cells has sparked interest in its potential as an anti-cancer therapy. Preclinical studies have shown promising results in various types of cancer, including breast, lung, and pancreatic cancer. The His tag on this protein also allows for easy purification, making it a valuable tool for research and drug development.

Conclusion

Recombinant Human TNFSF12, N-His is a modified version of the naturally occurring TNFSF12 protein, with an additional His tag at the N-terminus. It has a similar structure to the native protein and is a potent activator of the NF-κB signaling pathway. Its pro-inflammatory and pro-apoptotic effects make it a potential drug target for various diseases, including autoimmune disorders and cancer. The addition of the His tag also makes it a valuable tool for research and drug development. Further studies on this protein may lead to the development of novel therapies for a wide range of diseases.